Event-Related Potential (ERP) Components in Clinical Diagnosis

Last updated: December 24, 2024
Sponsor: Boston University
Overall Status: Suspended

Phase

N/A

Condition

Dementia

Memory Loss

Mild Cognitive Impairment

Treatment

Additional neuropsychological tests

Electroencephalogram (EEG) system

Standard Neuropsychological Testing

Clinical Study ID

NCT05673759
H-43360
  • Ages 20-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

In this study, the investigators will use a novel electroencephalogram (EEG) system that participants will wear during a single in-person research session to investigate whether ERPs are now ready for validation as a tool clinicians can easily implement to increase diagnostic accuracy and confidence. This EEG will not be used to treat, cure, mitigate or diagnosis any disease and there will be no safety or efficacy data collected about the machine for any purpose including support of FDA submission.

The investigators will compare the ERP data to that of neuropsychological testing in order to determine the degree of correlation between these two measures. Questionnaires on cognition, mood, and fluency will be administered prior to the EEG to establish a baseline. ERP data from the EEG session will be compared with the results of the neuropsychological battery in order to determine whether the implementation of ERPs in the existing workflow of clinicians can aid in diagnostic accuracy, thus altering clinical management.

Eligibility Criteria

Inclusion

Inclusion Criteria:

For Mild Alzheimer Disease (AD) dementia

  • Meets probable AD dementia National Institute on Aging and Alzheimer's Association (NIA-AA) criteria

  • 50-90 years old

  • Mini-Mental State Examination (MMSE) 20-27

  • Performance on delayed recall and recognition memory worse than 1.5 standarddeviation (SD) for age and education

  • Performance on delayed recall and recognition memory worse than 1.5 SD for age &education in at least one other cognitive domain (e.g., language, executivefunctioning) based on other tests in our neuropsychological test battery.

  • Dr. Turk and Dr. Budson will confirm all mild AD dementia diagnoses

For Mild cognitive impairment (MCI)

  • MCI due to any etiology 50-90 years old

  • MMSE > 23

  • Performance on delayed recall and recognition memory worse than 1.0 SD for age &education adjusted norms

  • Dr. Turk and Dr. Budson will confirm all MCI diagnoses

For Healthy older adults

  • 50-90 years old

  • Functioning normally in occupation determined by self-report

For Healthy younger adults

  • 20-50 years old

  • Functioning normally in occupation determined by self-report

Exclusion

Exclusion Criteria:

A clinically significant problem of any of the following conditions:

  • depression

  • heavy alcohol or drug use

  • cerebrovascular disease

  • a different degenerative disease (e.g., fronto-temporal dementia, Parkinson'sdisease)

  • any medical condition whose severity could significantly impair cognition (e.g.,organ failure)

  • on any antipsychotic or epilepsy medication

  • Unable to understand the consent form

Study Design

Total Participants: 200
Treatment Group(s): 3
Primary Treatment: Additional neuropsychological tests
Phase:
Study Start date:
March 06, 2023
Estimated Completion Date:
December 31, 2025

Study Description

A cross sectional cohort study design with four groups will be implemented to determine how ERPs can provide diagnostic information and alter clinical management beyond that of neuropsychological testing alone in patients with Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI).

Secondary Objectives:

  • To determine the impact of ERP testing (using cognitive health assessment reports) on change in research grade clinical diagnosis

  • To determine the degree of correlation between quantitative ERP measures with neuropsychological testing performance using a standardized neuropsychological battery.

    75 mild AD dementia and 75 MCI due to any etiology, 25 Older Adults (OA) and 25 Younger Adults (YA) will be enrolled over the course of two years. Each subject will participate in the study for 1 visit.

The in person 50-60-minute testing session consists of a neuropsychological battery, and an EEG session with computer tasks including the Auditory Oddball paradigm, a Continuous Visual Memory Test, Auditory Evoked Potentials, Visual Evoked Potentials, the Erikson Flanker Task, and the Hayling Task.

Connect with a study center

  • BU Alzheimer Disease Center

    Boston, Massachusetts 02118
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.